These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 83747)

  • 21. [Prostate-specific antigen. A new marker of prostatic pathology].
    Boccon-Gibod L; Géraud M; Dugué MA
    Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
    Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
    Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The study of T-, B-, O- lymphocytes in acute lymphoblastic leukemia.
    Bogusławska-Jaworska J; Chybicka A
    Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):859-66. PubMed ID: 312091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T and B lymphocytes in patients with hay fever.
    Małolepszy J; Kraus-Filarska M; Panaszek B; Liebhart E; Szeliga W; Litwa M
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):589-92. PubMed ID: 6970026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T- and B-lymphocyte subpopulations following radiotherapy for invasive squamous cell carcinoma of the uterine cervix.
    Rand RJ; Jenkins DM; Bulmer R
    Clin Exp Immunol; 1978 Jul; 33(1):159-65. PubMed ID: 309370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
    König JE; Senge T; Allhoff EP; König W
    Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience with prostate-specific antigen in patients with prostatic cancer].
    Romics I; Bach D
    Orv Hetil; 1989 Dec; 130(52):2797-800. PubMed ID: 2481833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of feline T and B cells.
    Kuramochi T; Takeishi M; Ishida T; Kato K; Ishida M
    Am J Vet Res; 1987 Feb; 48(2):183-5. PubMed ID: 3493718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum antibody levels of cytomegalovirus, herpes simplex type I and adenovirus in patients with benign or malignant prostatic neoplasms].
    Peker AF; Erkan I; Ozen HA; Ustaçelebi S; Ozdemir T
    Mikrobiyol Bul; 1986 Jul; 20(3):165-75. PubMed ID: 2436029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro study of cellular immunity in atopic and in contact eczema (author's transl)].
    Guilhou JJ; Clot J; Bousquet J; Téot M; Meynadier J
    Ann Dermatol Venereol; 1978 May; 105(5):513-8. PubMed ID: 309304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with the carbohydrate antigen CA-50 in the serum of patients with prostatic carcinoma: a preliminary report.
    Melloni D; Cacciatore M; Carreca I; Cigno A; Laconi A; Pavone-Macaluso M
    J Exp Pathol; 1987; 3(4):369-73. PubMed ID: 2457664
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of histamine on the spontaneous rosette formation.
    Małolepszy J; Szeliga W; Kraus-Filarska M; Panaszek B
    Arch Immunol Ther Exp (Warsz); 1980; 28(6):885-9. PubMed ID: 6266367
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutual relationship between total and active T lymphocytes in patients with malignant tumors.
    Babusíková O; Babusík P; Novotná L
    Neoplasma; 1978; 25(1):67-74. PubMed ID: 305544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T and B lymphocytes in malignant melanoma patients.
    Babusiková O; Novotná L; Schneková K; Turková D; Havránková M
    Neoplasma; 1976; 23(6):635-44. PubMed ID: 1087378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lymphocytes subpopulation in cancer's patients. Relationship with primitive anatomical location, histological type and clinical stage (author's transl)].
    Saiz Garcia F; Rodriguez Valverde V
    Bull Cancer; 1981; 68(1):32-9. PubMed ID: 6971668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
    Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC
    Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
    Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
    Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.